The results of genomic and molecular profiling can guide treatment decisions in several ways:
Targeted Therapy: Identifies specific mutations that can be targeted by existing drugs, allowing for more precise and effective treatments. Immunotherapy: Detects biomarkers that predict response to immunotherapy, such as PD-L1 expression or microsatellite instability. Clinical Trials: Matches patients with clinical trials investigating novel therapies targeting their specific genetic alterations. Risk Stratification: Assesses the risk of recurrence and progression, aiding in treatment planning and monitoring.
